We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis (ZTS) Librela Gets Marketing Authorization in Europe
Read MoreHide Full Article
Zoetis Inc. (ZTS - Free Report) announced that the European Commission granted marketing authorization to Librela (bedinvetmab), an injectable monoclonal antibody (mAb) therapy for monthly alleviation of osteoarthritis (OA) pain in dogs. Librela is the first injectable monoclonal antibody authorized for alleviation of osteoarthritis pain in dogs.
Shares of the company have increased 25.3% year to date against the industry’s decline of 4.3%.
Bedinvetmab has a unique mode of action, inhibiting Nerve Growth Factor—a key player in osteoarthritis pain— which effectively controls OA pain for a month along with offering a positive safety profile.
Bedinvetmab administered as monthly injections during the pivotal, field three-month study demonstrated a reduction in osteoarthritis pain as compared to placebo-controlled dogs. Furthermore, this pain reduction was maintained throughout the six-month continuation study,demonstrating sustained efficacy of bedinvetmab for at least nine months.
OA can affect many areas of a pet’s life, including sleep, cognitive function, affect (emotion) and social relationships, among several other factors.
Unlike other pain indications, Librela combines one month of pain control and increased mobility, with a proven safety and efficacy profile.
Cassava’s loss per share estimates have narrowed from 26 cents to 21 cents for 2020 in the past 60 days. Shares of the company have increased 116.1% year to date.
BioLineRx’s loss per share estimates have narrowed from $1.95 to $1.67 for 2020 and from $1.44 to $1.36 for 2021 in the past 60 days. Shares of the company have increased 4.4% year to date.
Catalent’s earnings per share estimates have increased from $2.41 to $2.51 for 2020 and from $2.82 to $2.93 for 2021 in the past 60 days. Shares of the company have decreased 81.8% year to date.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Zoetis (ZTS) Librela Gets Marketing Authorization in Europe
Zoetis Inc. (ZTS - Free Report) announced that the European Commission granted marketing authorization to Librela (bedinvetmab), an injectable monoclonal antibody (mAb) therapy for monthly alleviation of osteoarthritis (OA) pain in dogs. Librela is the first injectable monoclonal antibody authorized for alleviation of osteoarthritis pain in dogs.
Shares of the company have increased 25.3% year to date against the industry’s decline of 4.3%.
Bedinvetmab has a unique mode of action, inhibiting Nerve Growth Factor—a key player in osteoarthritis pain— which effectively controls OA pain for a month along with offering a positive safety profile.
Bedinvetmab administered as monthly injections during the pivotal, field three-month study demonstrated a reduction in osteoarthritis pain as compared to placebo-controlled dogs. Furthermore, this pain reduction was maintained throughout the six-month continuation study,demonstrating sustained efficacy of bedinvetmab for at least nine months.
OA can affect many areas of a pet’s life, including sleep, cognitive function, affect (emotion) and social relationships, among several other factors.
Unlike other pain indications, Librela combines one month of pain control and increased mobility, with a proven safety and efficacy profile.
Zacks Rank and Stocks to Consider
Zoetis currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Cassava Sciences Inc. (SAVA - Free Report) , BioLineRx Ltd, and Catalent Inc. (CTLT - Free Report) . All stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cassava’s loss per share estimates have narrowed from 26 cents to 21 cents for 2020 in the past 60 days. Shares of the company have increased 116.1% year to date.
BioLineRx’s loss per share estimates have narrowed from $1.95 to $1.67 for 2020 and from $1.44 to $1.36 for 2021 in the past 60 days. Shares of the company have increased 4.4% year to date.
Catalent’s earnings per share estimates have increased from $2.41 to $2.51 for 2020 and from $2.82 to $2.93 for 2021 in the past 60 days. Shares of the company have decreased 81.8% year to date.
Zoetis Inc. Price
Zoetis Inc. price | Zoetis Inc. Quote
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot stocks we're targeting >>